VS-ARM-01 // SOVEREIGN BIOHEALTH & CLINICAL INTELLIGENCE
Bridging MENA healthcare and pharma institutions with South Korea’s most mature biomanufacturing clusters and clinically proven AI engines. We do not deliver slide decks; we deploy forward-deployed capability architects directly to site.
THE STRATEGIC REALITY GAP
01 // BIOPROCESS GAP
Most regional initiatives stop at fill and finish. The real gap is control of the bioreactors, the upstream and downstream process, and a strict cGMP standard for vaccines and biosimilars.
02 // DATA SOVEREIGNTY
Commercial cloud AI puts national genomic and health data at risk of leaving the country. Advanced screening has to run inside the hospital’s own infrastructure, fully.
03 // IN SILICO R&D
Moving from conventional generics into oncology and immunology needs molecular modelling labs that cut years of costly bench work and fit the genetics of the region’s population.
DEPLOYABLE OPERATING UNITS
UNIT-01 // OPERATIONAL BIOPROCESS
Bioprocess Engineering & cGMP Transfer
Driven by VS-P02: Apex (Embedded Capability)Transfer the operating know-how of biomanufacturing from Songdo and Osong in South Korea. Forward-deployed process engineers and pharmacists work beside the plant on the reactors, the scale-up, and a national staff that can test and release on its own.
For: Biopharmaceutical plants, vaccine companies, and sovereign pharma arms such as Lifera, Mubadala Bio, and Gypto Pharma.
Mandate: A field operating mandate of 12 to 18 months.
UNIT-02 // CLINICAL AI & GENOMICS
Sovereign Clinical Diagnostics & AI
Driven by VS-P01: Aegis (Sovereign Infrastructure)Bring clinically adopted Korean diagnostic engines for chest, breast, and genomic screening into health systems and specialist hospitals, running fully on premises and air-gapped, with no link to a foreign cloud.
For: Medical cities, national cancer-screening programmes, genome centres, and specialist hospitals such as KFSHRC, departments of health, and ministries of health.
Mandate: An architecture and a pilot deployment in 6 to 9 months.
KOREA TO MENA // CAPABILITY PIPELINE
The world’s largest contract biomanufacturing capacity, for process control and the quality of production lines.
Preclinical testing and the development of complex bioprocess paths.
The technical groups behind clinically adopted imaging and genomic screening engines.
Choose the operating path your institution wants, and request a field brief. Capability engineering leadership reviews every request.
The request goes straight to the engineering team. Institutional confidentiality and data governance apply.